The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
Chemical Compound Review

SureCN194568     (4S)-4-[[(1S)-1-[[(1S)-1- [[(1R)-5-amino-1...

Synonyms: AC1L2XUK, AC1Q5QPK, Org 2766, AR-1K3777, LS-105755, ...
 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of Org 2766

 

Psychiatry related information on Org 2766

  • An ACTH 4-9 analog (Org 2766) and cognitive performance: high-dose efficacy and safety in dementia of the Alzheimer's type [6].
  • The rats were trained to respond for intracranial self-stimulation (ICS) and treated with control solution or varying doses of an ACTH 4--9 related synthetic peptide (Org 2766; H-Met(O2)-Glu-His-Phe-D-Lys-Phe-OH) [7].
  • Both peptides reduced exploratory head-dipping only at high doses (4-8 microgram/kg for Org 2766 and 200 microgram/kg for alpha-MSH); this change was not accompanied by a reduction in motor activity [8].
  • Contrasting effects of Org 2766 and alpha-MSH on social and exploratory behavior in the rat [8].
  • Intraperitoneal injection of Org 2766 (0.01-0.4 microgram/kg) produced a dose-related increase in the number of social contacts and in the time spent in active social interaction by pairs of male rats tested in arenas with which they were familiar, but had little effect when the rats were tested in unfamiliar arenas [8].
 

High impact information on Org 2766

  • Beneficial effect of Org 2766 in treatment of peripheral neuropathy in streptozocin-induced diabetic rats [1].
  • Apparently, the peptide Org 2766 has a protective action on nerve fibers and nerve function during STZ-induced diabetes [1].
  • Chronic subcutaneous treatment of diabetic rats with Org 2766 results in a significant enhancement of both motor and sensory nerve conduction velocity compared with saline-treated diabetic rats [1].
  • METHODS: To differentiate between cardiovascular deficits or neuronal impairment as a cause for these cardiovascular dysfunctions, we tested the effects of the ACTH4-9 analogue, Org 2766, a neurotrophic compound without cardiovascular effects, on arterial pressure, heart rate and baroreflex control of heart rate [4].
  • In order to understand the role of glucocorticoids in regulating ischemic cell death, we studied RU 38486, a glucocorticoid receptor blocker, and Org 2766, a non-steroidogenic adrenocorticotropic hormone 4-9 analog [9].
 

Chemical compound and disease context of Org 2766

  • Spontaneous motor activity in cold stressed 13 day old rats was prolonged by Org 2766, a substituted analogue of ACTH/MSH 4-9, (0.1 microgram/kg daily) but unaffected by the same dosage of ACTH/MSH 4-10 [10].
  • These results show that Org 2766 cannot completely prevent cisplatin neuropathy in young men with testicular cancer, but nerve damage may be ameliorated by the use of this ACTH (4-9) analogue [11].
 

Biological context of Org 2766

  • We examined whether Org 2766 stimulates nerve regeneration by enhancing or prolonging the expression of c-fos mRNA [12].
  • To study the putative binding sites of the neurotrophic peptide Org 2766, an analogue of ACTH(4-9) [H-Met(O2)-Glu-His-Phe-D-Lys-Phe-OH], biotinylated forms of the peptide were used [13].
  • The neurotrophic peptide Org 2766 does not influence the expression of the immediate early gene c-fos following sciatic nerve crush in the rat [12].
  • Release of neuropeptide (exocytosis) from axon endings was elevated after Taxol treatment, and exceptionally high in specimens cotreated with Taxol and Org 2766 (incubation time 22 h) [14].
  • Thus, it appears that Org 2766 provides the rapid effects in this system, by both accelerating some compensatory mechanisms necessary for functional recovery and promoting cell survival by providing neuronal protection [15].
 

Anatomical context of Org 2766

  • In order to differentiate between a vascular or an adrenergic-autonomic defect as the underlying cause of the disturbed nerve blood flow, we investigated the effects of the adrenocorticotropic hormone [ACTH]-(4-9) analogue Org 2766 on sciatic nerve blood flow under basal and adrenergic-stimulated conditions [16].
  • The binding was unevenly distributed over spinal cord structures and was displaceable by non-labelled Org 2766 to a limited extent (35%) [17].
  • The neurotrophic peptide Org 2766 accelerates the regeneration of peripheral nerves [12].
  • Evaluation of electrophysiological and clinical tests in an exploratory trial of Org 2766 in motor neuron disease [18].
  • Binding of a biotinylated neurotrophic ACTH(4-9) analogue, Org 2766, to neurofilament-positive cells in primary or cell line cultures [13].
 

Associations of Org 2766 with other chemical compounds

  • Both RU 38486 and Org 2766 treatment significantly (P<0.004) reduced hippocampal CA1 damage at day 4, but not on day 7 [9].
  • Twenty four patients with motor neuron disease (MND) participated in a double-blind, placebo-controlled trial with the ACTH 4-9 analog, Org 2766 [18].
  • Forty-two patients received at least four cycles of cisplatin (100 mg/m2 per cycle), together with subcutaneous injections of Org 2766 (2 mg/day for 5 consecutive days) or placebo [11].
  • The MSH/ACTH analog Org 2766 was investigated in patients suffering from social phobia.(ABSTRACT TRUNCATED AT 250 WORDS)[19]
  • In the present ultrastructural study, modulatory effects of Org 2766 on VCR-induced neurotoxicity were studied in vivo in neurons of the pond snail Lymnaea stagnalis, which has been shown previously to be a suitable test system to investigate neurotoxic side-effects of cytostatic agents [20].
 

Gene context of Org 2766

  • A broad range of peptides were used as representative models, viz., adrenocorticotropic hormone (ACTH), the modified ACTH fragment Org 2766, endorphins, cholecystokinin and fragments thereof [21].
  • The peptide ACTH 4--10 was ineffective, whereas another ACTH derivative H-Met(O2)-Glu-His-Phe-D-Lys-Phe-OH (Org 2766) reduced PRL release [22].
  • The effects (on human beings) of the ACTH analog Org 2766 were investigated for a range of performance tests: complicated serial reaction task, running memory span, verbal learning and non-verbal mental ability tests (closure flexibility and non-verbal abstraction) [23].
  • Analogues of ACTH-(4-9) (Org 2766) and ACTH-(4-10) (BIM 22015) are capable of sustaining neurite outgrowth from cultured dorsal root ganglion and spinal cord cells in the absence of nerve growth factor [24].
  • The effects of chronic treatment with the purported neurotrophic factor ACTH(4-9) analogue Org 2766 were studied on age-related degeneration of serotonergic fibres and on gliosis in the rat hippocampus and caudate putamen complex [25].
 

Analytical, diagnostic and therapeutic context of Org 2766

  • No side effects were seen after treatment with Org 2766 [26].
  • Contractile strength and motor unit performance during high frequency stimulation were significantly improved by Org 2766 treatment at both 7 and 11 days after crush denervation [27].
  • Enhancement of regeneration by Org 2766 after nerve crush depends on the type of neural injury [28].
  • Treatment with the neurotrophic peptide Org 2766, a synthetic ACTH4-9 analogue, prevents the occurrence of this sympathetic neuropathy, as the pupil diameters in the ACTH4-9 analogue-treated group are significantly (P < 0.05) larger than the pupils of placebo-treated rats, and are comparable to the pupil diameters of the rats in the control group [29].
  • We believe that Org 2766 does not have a long-term protecting effect on the EEG [30].

References

  1. Beneficial effect of Org 2766 in treatment of peripheral neuropathy in streptozocin-induced diabetic rats. Van der Zee, C.E., Van der Hoop, R.G., Gispen, W.H. Diabetes (1989) [Pubmed]
  2. The neurotrophic analogue of ACTH(4-9), Org 2766, protects against experimental allergic neuritis. Duckers, H.J., Verhaagen, J., Gispen, W.H. Brain (1993) [Pubmed]
  3. Effective use of a neurotrophic ACTH4-9 analogue in the treatment of a peripheral demyelinating syndrome (experimental allergic neuritis). An intervention study. Duckers, H.J., Verhaagen, J., de Bruijn, E., Gispen, W.H. Brain (1994) [Pubmed]
  4. In vivo cardiovascular reactivity and baroreflex activity in diabetic rats. Van Buren, T., Kasbergen, C.M., Gispen, W.H., De Wildt, D.J. Cardiovasc. Res. (1998) [Pubmed]
  5. A pilot study on the influence of a corticotropin (4-9) analogue on Vinca alkaloid-induced neuropathy. van Kooten, B., van Diemen, H.A., Groenhout, K.M., Huijgens, P.C., Ossenkoppele, G.J., Nauta, J.J., Heimans, J.J. Arch. Neurol. (1992) [Pubmed]
  6. An ACTH 4-9 analog (Org 2766) and cognitive performance: high-dose efficacy and safety in dementia of the Alzheimer's type. Miller, T.P., Fong, K., Tinklenberg, J.R. Biol. Psychiatry (1993) [Pubmed]
  7. Effects of an ACTH 4--9 related peptide upon intracranial self stimulation and general activity in the rat. Katz, R.J. Psychopharmacology (Berl.) (1980) [Pubmed]
  8. Contrasting effects of Org 2766 and alpha-MSH on social and exploratory behavior in the rat. File, S.E. Peptides (1981) [Pubmed]
  9. Regulation of ischemic cell death by glucocorticoids and adrenocorticotropic hormone. Antonawich, F.J., Miller, G., Rigsby, D.C., Davis, J.N. Neuroscience (1999) [Pubmed]
  10. Peptide influences on the development and regeneration of motor performance. Saint-Côme, C., Acker, G.R., Strand, F.L. Peptides (1982) [Pubmed]
  11. The effects of an ACTH (4-9) analogue on development of cisplatin neuropathy in testicular cancer: a randomized trial. van Gerven, J.M., Hovestadt, A., Moll, J.W., Rodenburg, C.J., Splinter, T.A., van Oosterom, A.T., Keizer, L., Drogendijk, T.E., Groenhout, C.M., Vecht, C.J. J. Neurol. (1994) [Pubmed]
  12. The neurotrophic peptide Org 2766 does not influence the expression of the immediate early gene c-fos following sciatic nerve crush in the rat. Plantinga, L.C., Verhaagen, J., Wong, S.L., Edwards, P.M., Bär, P.R., Gispen, W.H. Int. J. Dev. Neurosci. (1994) [Pubmed]
  13. Binding of a biotinylated neurotrophic ACTH(4-9) analogue, Org 2766, to neurofilament-positive cells in primary or cell line cultures. van Huizen, F., Philipsen, H.L., Draaijer, J., Hermkens, P.H., ten Kortenaar, P.B., Tonnaer, J.A. Peptides (1993) [Pubmed]
  14. Ultrastructural neuropathologic effects of Taxol on neurons of the freshwater snail Lymnaea stagnalis. Boer, H.H., Moorer-van Delft, C.M., Müller, L.J., Kiburg, B., Vermorken, J.B., Heimans, J.J. J. Neurooncol. (1995) [Pubmed]
  15. Specificity versus redundancy of melanocortins in nerve regeneration. Antonawich, F.J., Azmitia, E.C., Kramer, H.K., Strand, F.L. Ann. N. Y. Acad. Sci. (1994) [Pubmed]
  16. Presynaptic deficit of sympathetic nerves: a cause for disturbed sciatic nerve blood flow responsiveness in diabetic rats. Van Buren, T., Kasbergen, C.M., Gispen, W.H., De Wildt, D.J. Eur. J. Pharmacol. (1996) [Pubmed]
  17. Binding of the neurotrophic peptide Org 2766 to rat spinal cord sections is affected by a sciatic nerve crush. Dekker, A.J., Tonnaer, J.A. Brain Res. (1989) [Pubmed]
  18. Evaluation of electrophysiological and clinical tests in an exploratory trial of Org 2766 in motor neuron disease. Hesselmans, L.F., Wieneke, G.H., Oey, P.L., Groenhout, D.M., van der Graaf, Y., Gispen, W.H., Jennekens, F.G. Neuromuscul. Disord. (1993) [Pubmed]
  19. Recent developments in the psychopharmacology of social phobia. Den Boer, J.A., van Vliet, I.M., Westenberg, H.G. European archives of psychiatry and clinical neuroscience. (1995) [Pubmed]
  20. In vivo modulation of vincristine-induced neurotoxicity in Lymnaea stagnalis, by the ACTH(4-9) analogue Org 2766. Kiburg, B., Moorer-van Delft, C., Heimans, J.J., Huijgens, P.C., Boer, H.H. J. Neurooncol. (1996) [Pubmed]
  21. Capillary zone electrophoresis of pharmaceutical peptides. Langenhuizen, M.H., Janssen, P.S. J. Chromatogr. (1993) [Pubmed]
  22. Antagonism of pentobarbital-induced hormonal changes by TRH in rats. Taché, Y., Ruisseau, P.D., Ducharme, J.R., Collu, R. Eur. J. Pharmacol. (1977) [Pubmed]
  23. Some effects of an ACTH 4-9 analog (Org 2766) on human performance. Gaillard, A.W., Varey, C.A. Physiol. Behav. (1979) [Pubmed]
  24. Melanotropins as growth factors. Strand, F.L., Zuccarelli, L.A., Williams, K.A., Lee, S.J., Lee, T.S., Antonawich, F.J., Alves, S.E. Ann. N. Y. Acad. Sci. (1993) [Pubmed]
  25. Serotonergic fibres degenerating in the aging rat brain or sprouting from grafted fetal neurons are not affected by the neurotrophic ACTH analogue Org 2766. van Luijtelaar, M.G., Tonnaer, J.A., Steinbusch, H.W. J. Chem. Neuroanat. (1992) [Pubmed]
  26. Prevention of cisplatin neurotoxicity with an ACTH(4-9) analogue in patients with ovarian cancer. van der Hoop, R.G., Vecht, C.J., van der Burg, M.E., Elderson, A., Boogerd, W., Heimans, J.J., Vries, E.P., van Houwelingen, J.C., Jennekens, F.G., Gispen, W.H. N. Engl. J. Med. (1990) [Pubmed]
  27. ACTH 4-9 analog (Org 2766) improves qualitative and quantitative aspects of motor nerve regeneration. Saint-Come, C.M., Strand, F.L. Peptides (1988) [Pubmed]
  28. Enhancement of regeneration by Org 2766 after nerve crush depends on the type of neural injury. Tonnaer, J.A., Schuijers, G.J., Van Diepen, H.A., Peeters, B.W. Eur. J. Pharmacol. (1992) [Pubmed]
  29. Beneficial effect of an ACTH4-9 analogue on experimentally induced diabetic autonomic neuropathy in the eye of the rat under general anaesthesia. Vandertop, W.P., de Vries, W.B., Notermans, N.C., Tulleken, C.A., Gispen, W.H. J. Auton. Nerv. Syst. (1995) [Pubmed]
  30. Does an ACTH derivative (Org 2766) prevent deterioration of EEG in Alzheimer's disease? Partanen, J.V., Soininen, H., Riekkinen, P.J. Electroencephalography and clinical neurophysiology. (1986) [Pubmed]
 
WikiGenes - Universities